Dasatinib is FDA approved for patients whose chronic myeloid leukemia and ALL in patients who failed to respond to Gleevec, which is considered the standard of therapy for the disorder. The identification of molecular markers predictive of response to dasatinib could assist in clinical development by selecting patients most likely to derive clinical benefit. It is under study for breast cancer: a phase II study of it as a single agent and a Phase I study with capecitabine. It is a highly experimental agent that is not being used for bresat cancer outside of clinical trials. It is not medically necessary as generally defined.
L. Pusztai, K. Anderson, and K. R. Hess
Pharmacogenomic Predictor Discovery in Phase II Clinical Trials for Breast Cancer
Clin. Cancer Res., October 15, 2007; 13(20): 6080 – 6086.
K. S. Garman, J. R. Nevins, and A. Potti
Genomic strategies for personalized cancer therapy
Hum. Mol. Genet., October 15, 2007; 16(R2): R226 – R232.
Fei Huang et al, Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection Cancer Research 67, 2226-2238, March 1, 2007.